Results 61 to 70 of about 127,164 (309)

Hypoglycemic and pancreatic protective effects of freeze-dried strawberries in alloxan-induced diabetic rats: implications for pharmaceutical application [PDF]

Romanian Journal of Pharmaceutical Practice
Background and objectives. Freeze-dried strawberries (FDS) are rich in bioactive compounds with potential antidiabetic properties. This study evaluated the hypoglycemic effects and pancreatic protective activity of FDS in an alloxan-induced diabetic rat ...
Ardyarini Dyah Savitri, Lysa Veterini, Akbar R. Muhammad, Devy Yahya, Sony Wibisono, Widjiati, Soetjipto   +6 more
doaj   +1 more source

Synthesis of Biguanides as Potential hypoglycemic Agents: Some heterocyclic Derivatives

, 1966
Synthesis of Biguanides as Potential hypoglycemic Agents: Some heterocyclic ...
Auditi Kumar Acharyya, U. P. Basu, D. N. Ray   +2 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Unveiling the Chemistry of Citrus Peel: Insights into Nutraceutical Potential and Therapeutic Applications

Foods
The recent millennium has witnessed a notable shift in consumer focus towards natural products for addressing lifestyle-related disorders, driven by their safety and cost-effectiveness.
Hussan Munir, Sanabil Yaqoob, Kanza Aziz Awan, Aysha Imtiaz, Hiba Naveed, Naveed Ahmad, Muhammad Naeem, Waleed Sultan, Yongkun Ma   +8 more
doaj   +1 more source

Baseline characteristics stratified by baseline BMI in hypoglycemic treatments.

, 2016
Baseline characteristics stratified by baseline BMI in hypoglycemic treatments.
Xiaoling Cai (319173), Lingli Zhou (539752), Wenjia Yang (2865512), Linong Ji (131708), Xueyao Han (319175), Xueying Gao (2865509)   +5 more
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Treatment of gestational diabetes: oral hypoglycemic agents or insulin? [PDF]

, 2011
Our report aims to verify whether perinatal maternal glycemic control in gestational diabetes can only be achieved with insulin or with oral hypoglycemic agents.
Renda, Eliana, Giorgio, Elsa, valenti , Oriana, Hyseni, Entela, Monte, Santo, De Domenico, Roberta, Faraci, Marianna, Di Prima, Fosca A. F.   +7 more
core   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

Uncovering undetected hypoglycemic events

, 2012
Jeff UngerCatalina Research Institute, Chino, CA, USAAbstract: Hypoglycemia is the rate-limiting factor that often prevents patients with diabetes from safely and effectively achieving their glycemic goals.
Unger J
core  

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source